Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribupatide vs Semaglutide and Placebo in Obesity
NCT07284979Phase 3Active, not recruiting
- Sponsor
- Kailera Therapeutics
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Modality
- Peptides, Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of ribupatide in obesity, sponsored by Kailera Therapeutics. Started Dec 2025; status: active, not recruiting.
02
Drugs
ribupatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07284979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284979.